Multivariate analysis for association of recipient and/or donor statin use with various outcomes compared with control group (R−/D−, n = 340) among recipients with CSP-based GVHD prophylaxis
| Endpoint . | (R+/D−, n = 13) . | (R−/D+, n = 54) . | (R+/D+, n = 10) . | |||
|---|---|---|---|---|---|---|
| HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . | |
| Grade 2-4 GVHD | 1.10 (0.5-2.3) | .79 | 0.79 (0.5-1.2) | .23 | 0.22 (0.1-0.9) | .03 |
| Grade 3-4 GVHD | 1.76 (0.6-5.0) | .29 | 0.00 (undefined) | < .001 | 0.00 (undefined) | .06 |
| Chronic GVHD | 0.79 (0.4-1.6) | .53 | 0.94 (0.6-1.4) | .76 | 0.59 (0.2-1.5) | .25 |
| Relapse/disease progression | 1.27 (0.4-3.6) | .66 | 0.72 (0.4-1.3) | .30 | 1.04 (0.3-4.3) | .95 |
| NRM | 0.36 (0.1-1.1) | .08 | 0.67 (0.4-1.2) | .15 | 0.86 (0.3-2.7) | .80 |
| Overall mortality | 0.53 (0.2-1.2) | .14 | 0.75 (0.5-1.1) | .18 | 1.00 (0.4-2.5) | .99 |
| Endpoint . | (R+/D−, n = 13) . | (R−/D+, n = 54) . | (R+/D+, n = 10) . | |||
|---|---|---|---|---|---|---|
| HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . | |
| Grade 2-4 GVHD | 1.10 (0.5-2.3) | .79 | 0.79 (0.5-1.2) | .23 | 0.22 (0.1-0.9) | .03 |
| Grade 3-4 GVHD | 1.76 (0.6-5.0) | .29 | 0.00 (undefined) | < .001 | 0.00 (undefined) | .06 |
| Chronic GVHD | 0.79 (0.4-1.6) | .53 | 0.94 (0.6-1.4) | .76 | 0.59 (0.2-1.5) | .25 |
| Relapse/disease progression | 1.27 (0.4-3.6) | .66 | 0.72 (0.4-1.3) | .30 | 1.04 (0.3-4.3) | .95 |
| NRM | 0.36 (0.1-1.1) | .08 | 0.67 (0.4-1.2) | .15 | 0.86 (0.3-2.7) | .80 |
| Overall mortality | 0.53 (0.2-1.2) | .14 | 0.75 (0.5-1.1) | .18 | 1.00 (0.4-2.5) | .99 |
HR and P values were adjusted for female → male sex mismatch, conditioning intensity, donor age more than 50 years, patient age more than 50 years, and disease risk.